Target Therapy and Immunotherapy for Gastric Cancer - Recent Updates

Gastric cancer, with more than 1 million cases all over the globe, is a leading contributor to cancer mortality. In the recent past, the evolution of target therapies and the refining of the already existing chemotherapy have widened the therapeutic choices for advanced gastric cancer to increase survival. In addition, more studies have been conducted all over the globe to extensively evaluate epigenomic and genomic heterogeneity of gastric cancer, leading to the recognition of new sensitive and specific prognostic and predictive biomarkers and the development of new molecular tumor classifications based on their molecular profiling. But, many clinical studies aimed at evaluating the efficiency of certain new molecular targets gave negative results. Hence, it is vital to further study the molecular features of subtypes of gastric carcinoma for the purpose of identifying new tools for selecting responsive tumor subtypes for future trials. This review provides an overview of recent developments of target therapy and immunotherapy in advanced gastric cancer.